The efficacy of cefuroxime, a new cephalosporin, was studied in 30 children, of whom 18 had a urinary infection and 12 a respiratory infection.
Patients were also to be withdrawn from the study if any allergic reaction developed during treatment or if there was no response within 4 days.
Urinary Tract Infection (UTI)
The diagnosis was confirmed before treatment was commenced by bladder puncture or by 2 mid-stream or bag urine samples. A blood culture was taken in every case. The control samples were taken on the second to fourth and on the seventh days of treatment and 1 and 4 weeks after completed treatment. The mean dose of cefuroxime was 15.0 mg/kg given three times daily. The mean treatment period was 7.3 days.
Respiratory Tract Infection (RTI) Throat swabs, myringotomy samples and blood cultures were taken for bacteriological analysis. Appropriate X-ray films were available to confirm the diagnosis. The mean dose of cefuroxime was 15.7 mg/kg given three times daily. The mean treatment period was 8.1 days.
Bacteriological Investigations
The-, specimens were tested for sensitivity using 30 ,ug cefuroxime discs with which an inhibition zone diameter of 27-28 mm represents a high sensitivity. This is equivalent to a desirable serum concentration of cefuroxime of 1.6 ,ug/ml when tested on 10 Escherichia coli strains. The corresponding figures for cephalexin are 25 mm and 2 ,tg/ml and for cephalothin 24 mm and 2 ,ug/ml (Renkonen, personal communication) .
The sensitivity test discs were made by the ICS method on Mueller-Hinton agar. Heated blood was added to the nutrient broth when studying Hwmophilus, Pneumococcus and Group A hmmolytic Streptococcus strains.
Laboratory Tests
The following tests were done on every patient at the beginning and end of the treatment period and 1 week after completion of treatment: hemoglobin, leucocytes and differential count, thrombocytes, ESR, normotest (factors If, VII, X), serum protein, serum bilirubin (total), serum transaminases SGOT and SGPT, serum alkaline phosphatase, creatinine and creatinine phosphate and urinary sediment (protein, blood cells, casts).
Classification ofResults
Results were classified as follows:
Good in urinary tract infections when the urine cleared and clinical symptoms disappeared within 2-3 days; in respiratory tract infections when the main clinical symptoms, fever and rales, disappeared within 3-4 days; and in otitis when the cultures of the middle ear exudate were sterile and middle ears were free from exudate after treatment.
Partial in respiratory tract infections when the main clinical symptoms disappeared within 3-4 days, but cough and coryza were still present; in otitis when middle ear exudate was still present but sterile.
Failure when there was no clinical or bacteriological response.
RESULTS

Urinary Tract Infection
Eighteen children had a urinary tract infection and the details of this group are given in Table 1 . The urine cleared during the first 3 days of treat- None None a =all bacteria isolated were cultured from myringotomy exudate ment in all cases. Four patients suffered a reinfection during a 4-week follow-up period. Two of these patients had a unilateral reflux of urine to the renal pelvis on a micturating cystogram, which was performed on every patient 6 weeks or more after the acute infection. All reinfections were confirmed by bladder puncture. In case No. 3 a reinfection caused by a resistant Proteus morgani was diagnosed one week after treatment. The primary infection was caused by Escherichia coli. In cases No. 9 and 14 reinfection occurred with a cefuroxime-sensitive Escherichia coli 1 week after treatment. In case No. 8 reinfection by an Enterococcus occurred 4 weeks after treatment. This organism was resistant to cephalexin and cephalothin but was not tested against cefuroxime. The only primary infection with Enterococcus cleared well and this organism was sensitive to cefuroxime but resistant to cephalexin and cephalothin.
Respiratory Tract Infection
Twelve children had a respiratory tract infection. The details of this group are given in Table 2 . In case No. 5 there was a reinfection of the otitis I week after treatment, caused by a Haemophilus. During cefuroxime treatment the middle ear exudate became sterile but did not disappear. In case No. 10, both during and after treatment, cefuroxime-sensitive bacteria were cultured from the middle ear exudate. In case No. 6 the otitis was caused by a Hazmophilus resistant to cephalexin and cephalothin but sensitive to cefuroxime and treatment was successful.
Side-effects
No serious side-effects were reported. Abnormalities of liver function are shown in Table 3 .
The transient, marked rise of SGOT and SGPT in case No. 5 (UTI) is probably due to cefuroxime, but the rise of enzymes 2 weeks after treatment is possibly due to nitrofurantoin or to an interaction of cefuroxime and nitrofurantoin on the liver. In cases No. 17 (UTI) and 9 (RTI) the slight increases are almost within the normal range and possibly due to the i.m. injections.
In case No. 10 (UTI) liver enzymes were normal at the end of treatment, but after 1 week of nitrofurantoin there was a transient rise of SGOT to 99 U/I and SGPT to 111 U/l. A similar phenomenon was observed in case No. 5 (UTI Table 3 ). Professor Kouvalainen (Chairman) said that there were 4 reinfections in the urinary tract in Dr Nyman's series. In 2 the organism was a sensitive Escherichia coli. He wondered why these reinfections with sensitive E. coli should be seen.
Dr Nyman said that 2 of the patients had urinary reflux shown on the pyelogram. This reflux into the renal pelvis might have been a contributory factor in reinfection. As to Staphylococcal otitis, the infection was caused by S. aureus which was also sensitive to penicillin. Cefuroxime-sensitive bacteria were grown from the middle ear exudate at the beginning and end of therapy and 1 week after the completion of treatment. Perhaps there had been contamination from the external auditory canal in taking the sample.
Dr Renlund said that the meningitis patient, possibly suffering from Staphylococcus aureus, was 6 weeks premature with a birth weight of 2580 g and had received 30 mg/kg of cefuroxime in 3 daily doses for 6 days for pulmonary infection. After this time the patient became very ill with fever. He had a leucocyte count in blood of 28-32 x 103 and in cerebrospinal fluid a protein content of 3.2 g/l, glucose of 0.9 mg/100 ml, erythrocytes of 30,000 and leucocytes of 3400/mI. The clinical picture looked very like meningitis. Culture showed Staphylococcus aureus which might have been contamination, but in the same sample the cefuroxime concentration was 2.3 ,tg/ ml which should have been sufficient to destroy any Staphylococcus. In addition, the organism was shown to be sensitive to cefuroxime. The child recovered when given penicillin.
Professor Pettay asked if there were any data on the possibility of curing meningococcal carriers with cefuroxime.
Professor Rosachino said that in Italy, and he believed throughout Europe, Meningococcus was sensitive to penicillin. It was therefore inappropriate to use cefuroxime for meningococcal infections or carriers.
Professor Kouvalainen (Chairman) then turned his attention to side-effects. They were few: some rashes, some elevation of liver enzymes and possibly elevated blood urea nitrogen. Cefuroxime was quite a safe drug.
However, he questioned the significance of very high peak levels of cefuroxime. With streptomycin for example, it was unnecessary to have high levels for long periods, and levels of more than 10 mg/kg often led to subsequent hearing loss.
Only one patient, case No. 1 (RTI) complained of pain on injection on days 2-5 of treatment, which subsided during the subsequent treatment days. Two 
Conclusions
In general, cefuroxime was found to be a very satisfactory antibiotic in the treatment of pediatric infections. Intramuscular administration was harmless and no serious side-effects were noted.
DISCUSSION
Professor Kouvalainen (Chairman) invited discussion on the effectiveness of cefuroxime and then on its side-effects.
Professor C Simon (Kiel) had no doubt that cefuroxime was an effective drug in upper and lower respiratory tract infection in children. However, he did not believe that cefuroxime should be recommended in all cases of infection if there were no other disease present. They usually started treating children with an oral drug, for example penicillin V, amoxycillin or cotrimoxazole. Only in the compromised patient in hospital, where resistant organisms might be involved, did it seem justified to treat an upper respiratory tract infection with cefuroxime. Dr Nyman agreed. Patients in his study were those for whom i.m. antibiotic therapy seemed appropriate. They were of pre-school age and on arrival at hospital were vomiting or presenting a complicated clinical picture, especially those with urinary tract infection. Normally, when there were no complications then children were given oral therapy.
Professor H C Neu (New York) was concerned that 3 investigators had failures with Staphylococcus aureus. One was an otitis, one a meningitis and one a pulmonary infection. Considering the known inhibitory concentrations of cefuroxime for Staphylococci and the pharmacokinetics which had been presented, there should have been present a 20-50-fold excess over the MIC.
One use of this drug would presumably be in patients who were allergic to penicillin.
He asked how other investigators compared this drug to other cephalosporins, for example cephalothin and cefazolin.
Mrs B M Mullinger (Greenford) asked Professor Rosachino to clarify the hemoglobin levels he had described after treatment.
Professor Rosachino said that the mean level had been 13.4 and the maximum 14.9 g/100 ml.
Professor Kouvalainen (Chairman) said that eosinophilia after infection might sometimes be seen. But it was very difficult to establish if eosinophilia in a patient who had received antibiotics was due to the infection or to sensitization to the drug. Dr 0 Ogundipe (Lagos) said that throughout the Conference, slight elevations of SGPT and SGOT had not been regarded as very significant. He asked for the results of Coombs' tests in any of the patients taking the drug.
Dr Wilkinson said that Coombs' tests had been performed on some of the newborn groups. The availability of blood had limited the number, but in those patients where the test was performed before and after treatment, none had become positive.
Professor Kouvalainen (Chairman) in conclusion said that cefuroxime appeared to be a promising drug for pediatric use.
